Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
By Amrutha Penumudi and Rosmi Shaji The U.S. Food and Drug Administration's staff reviewers did not raise any major red flags over Intercept Pharmaceuticals Inc's liver drug on Tuesday, sending the stock up as much as 19 percent.
Aldeyra Therapeutics Inc said its eye drug was more effective than a placebo in treating itching and tearing associated with allergic conjunctivitis in a mid-stage study.
PTC Therapeutics Inc's shares plummeted more than 50 percent on Tuesday, after the U.S. Food and Drug Administration said the company's marketing application for a muscle disorder drug was insufficient to warrant a review.
Drugmaker Perrigo Co Plc's adjusted profit missed market estimates for the first time in five quarters as sales in its branded consumer healthcare business disappointed.
Regulus Therapeutics Inc said interim mid-stage data for its hepatitis C combination drug showed it had the potential to sharply reduce the duration of the treatment to four weeks from 12 weeks.
Medical device maker Stryker Corp said it would buy Physio-Control International Inc for $1.28 billion in cash to expand its emergency medical services business and raised its full-year earnings forecast for the second time this month.
Regeneron Pharmaceuticals Inc reported lower-than-expected quarterly sales for its new cholesterol drug and reiterated expectations of a "gradual uptake" for the treatment, which has been tipped to be its next blockbuster.
Heart device maker Boston Scientific Corp's quarterly revenue fell just shy of Wall Street expectations as sales in its second-biggest unit fell, sending its shares down as much as 6 percent.
Abbott Laboratories said it would buy Alere Inc for $5.8 billion to become a leader in point-of-care testing, a fast-growing market as physicians increasingly adopt rapid tests that speed up treatment.
St. Jude Medical Inc said the U.S. Food and Drug Administration has issued a Class I recall on faulty parts of its devices implanted into patients to control irregular heartbeats.